"Neurotensin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biologically active tridecapeptide isolated from the hypothalamus. It has been shown to induce hypotension in the rat, to stimulate contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duodenum. There is also evidence that it acts as both a peripheral and a central nervous system neurotransmitter.
Descriptor ID |
D009496
|
MeSH Number(s) |
D12.644.400.550 D12.776.631.650.550
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neurotensin".
Below are MeSH descriptors whose meaning is more specific than "Neurotensin".
This graph shows the total number of publications written about "Neurotensin" by people in this website by year, and whether "Neurotensin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1995 | 1 | 0 | 1 |
1996 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2005 | 3 | 0 | 3 |
2008 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurotensin" by people in Profiles.
-
McHenry JA, Otis JM, Rossi MA, Robinson JE, Kosyk O, Miller NW, McElligott ZA, Budygin EA, Rubinow DR, Stuber GD. Hormonal gain control of a medial preoptic area social reward circuit. Nat Neurosci. 2017 Mar; 20(3):449-458.
-
Choi KE, Hall CL, Sun JM, Wei L, Mohamad O, Dix TA, Yu SP. A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice. FASEB J. 2012 Jul; 26(7):2799-810.
-
Hughes FM, Shaner BE, May LA, Zotian L, Brower JO, Woods RJ, Cash M, Morrow D, Massa F, Mazella J, Dix TA. Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. J Med Chem. 2010 Jun 24; 53(12):4623-32.
-
Orwig KS, Lassetter MR, Hadden MK, Dix TA. Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. J Med Chem. 2009 Apr 09; 52(7):1803-13.
-
Torregrossa MM, Kalivas PW. Neurotensin in the ventral pallidum increases extracellular gamma-aminobutyric acid and differentially affects cue- and cocaine-primed reinstatement. J Pharmacol Exp Ther. 2008 May; 325(2):556-66.
-
Hadden MK, Orwig KS, Kokko KP, Mazella J, Dix TA. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology. 2005 Dec; 49(8):1149-59.
-
Hadden MK, Walle T, Dix TA. Cellular uptake of a radiolabelled analogue of neurotensin in the Caco-2 cell model. J Pharm Pharmacol. 2005 Mar; 57(3):327-33.
-
Kokko KP, Hadden MK, Price KL, Orwig KS, See RE, Dix TA. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier. Neuropharmacology. 2005 Mar; 48(3):417-25.
-
Kokko KP, Hadden MK, Orwig KS, Mazella J, Dix TA. In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues. J Med Chem. 2003 Sep 11; 46(19):4141-8.
-
Kokko KP, Dix TA. Monitoring neurotensin[8-13] degradation in human and rat serum utilizing matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem. 2002 Sep 01; 308(1):34-41.